Filing summary
Filing and period: The supplied document is NeoStem, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 2, 2015. This does not match the request metadata identifying Lisata Therapeutics, Inc. and “2013 Q4.” The summary below reflects the filing provided.
Business context
NeoStem was a clinical-stage cell-therapy company with a cell-therapy manufacturing and services business through wholly owned Progenitor Cell Therapy (PCT). Its principal programs were NBS20 for metastatic melanoma, NBS10 for ischemic injury following heart attack, and NBS03D, a regulatory T-cell therapy for type 1 diabetes. The company had no approved products and had not generated product-sales revenue. In May 2014, it acquired California Stem Cell, adding the NBS20 program.
Financial performance and position
| Metric | FY 2014 | FY 2013 | Change / context |
|---|---|---|---|
| Revenue | $17.9 million | $14.7 million | Up 22%; primarily services, processing and storage |
| Gross profit and margin | $2.3 million; 13% | $1.7 million; 12% | Improved modestly; cost of revenue rose 21% |
| Operating loss | $57.7 million | $36.8 million | Loss widened as operating expenses rose 47% |
| Net loss from continuing operations | $55.5 million | $39.5 million | Loss widened |
| Net loss attributable to common stockholders | $54.9 million; $1.68 per share | $39.0 million; $1.90 per share | Per-share loss narrowed as weighted-average shares increased |
| Cash used in operating activities | $46.9 million | $27.1 million | Cash burn increased materially |
| Cash, cash equivalents and marketable securities | $26.3 million | $46.1 million | Year-end balance declined; cash and equivalents alone were $19.2 million |
| Working capital | $20.0 million | Not stated in the cited comparison | At December 31, 2014 |
| Debt and notes payable | $16.6 million | $1.4 million | Includes $15.0 million Oxford term loan and $1.6 million notes payable; mortgages were repaid |
Research and development expense increased to $29.2 million from $16.9 million, reflecting development spending across the acquired oncology program, NBS10 and the Treg program. SG&A rose to $30.8 million from $21.6 million, including increased infrastructure and share-based compensation. Other income of $2.9 million in 2014 largely reflected a reduction in the estimated NBS10 contingent consideration liability, partly offset by higher estimated CSC milestone consideration. Share-based compensation totaled $11.2 million.
For Q4 2014, revenue was $5.3 million versus $4.1 million in Q4 2013; operating expenses were $20.8 million versus $14.6 million; continuing-operations net loss was $11.7 million versus $12.7 million; and loss per share was $0.32 versus $0.47.
Material changes and financing
- The CSC acquisition closed May 8, 2014. NeoStem issued approximately 5.33 million shares and recorded $11.9 million of contingent milestone consideration; additional milestone payments could total up to $90 million, payable in cash or shares at NeoStem’s discretion.
- NeoStem raised approximately $16.7 million from common-stock issuance and $1.7 million from warrant exercises during 2014. It also received a $15.0 million Oxford loan; after repaying TD Bank debt and related costs, net loan proceeds were approximately $11.3 million.
- The Oxford loan bears 8.5% interest, matures September 2018, and is secured by substantially all assets other than intellectual property, as well as subsidiary shares. A further $5.0 million draw was conditional on a qualifying NBS10 strategic arrangement and at least $10.0 million upfront payment by September 19, 2015.
- At year-end, $19.1 million remained available under the $30 million Aspire stock-purchase agreement. Aspire purchased a further approximately $4.4 million of shares from January 1 through March 1, 2015.
Outlook, risks and unusual items
- Management stated that available cash, service revenue and access to the Aspire agreement were expected to fund operations for the next 12 months, while also warning that substantial additional capital would be needed for longer-term development and growth. Failure to raise capital could delay or discontinue programs and expansion.
- The Intus Phase 3 trial of NBS20 was planned for 250 patients, with first randomization expected in Q2 2015 and enrollment targeted for completion in Q4 2016. The filing gives differing cost estimates for the trial: approximately $25 million in the risk discussion and approximately $43 million in the liquidity outlook.
- For NBS10, the Phase 2 PreSERVE analysis reported exploratory, post hoc dose-related findings, including statistically significant results in a highest-dose subgroup of 15 patients. Overall NBS10 was not statistically significant versus placebo on certain measures; the SPECT perfusion hypothesis was not supported. Management planned further follow-up and FDA discussions, with development next steps expected in the second half of 2015.
- Management planned a Phase 2 NBS03D diabetes trial in late 2015 or 2016, subject to resource availability. Timing and prioritization of other programs could change with financing and clinical results.
- Key risks include continuing losses and cash burn, potential equity dilution and financing constraints, uncertain clinical efficacy and regulatory approval, trial enrollment and manufacturing challenges, dependence on third-party reagents and a concentrated customer/receivables base. Four customers represented 48% of 2014 revenue and 68% of year-end accounts receivable.
- The company reported no legal proceedings and no off-balance-sheet arrangements. The auditor gave unqualified opinions on the financial statements and internal control over financial reporting; management also assessed disclosure controls and internal controls as effective.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied filing is NeoStem FY2014, not a Lisata Therapeutics 2013 filing.
- Reconcile the stated Intus trial cost estimates of $25 million and $43 million, and assess the full funding requirement relative to cash, burn rate and remaining Aspire capacity.
- Review the full PreSERVE AMI results and distinguish prespecified outcomes from post hoc subgroup findings; verify subsequent FDA feedback and development decisions.
- Track dilution from Aspire sales, outstanding options and warrants, and potential CSC milestone shares or payments.
- Assess the assumptions underlying contingent consideration, acquired in-process R&D and goodwill valuations, and the concentration of customer revenue and receivables.